← Back to Patent Explorer
US5310883A Expired / Lapsed US ⏱️ 0.0 years remaining

Chimeric fibroblast growth factors

Assignee: Wyeth Holdings LLC
•
Filing: 1991-11-04
•
Granted: 1994-05-10
•
Expires: 2011-11-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to novel chimeric fibroblast growth factors (FGF) wherein the alanine at amino acid 3 and serine 5 of native human recombinant basic fibroblast growth factor are replaced with glutamic acid. The N-terminus sequence of the present chimeric FGFs identify homology with that of human acidic fibroblast growth factor. The mitogenic properties of the native human recombinant basic FGF are exhibited by the present chimeric FGFs, and they are efficiently expressed in E. coli at significantly greater yields that previously reported. Novel variants of this new glu 3 ,5 basic fibroblast growth factor, such as those in which cysteine 78 and cysteine 96 are replaced, e.g., with serine or other amino acids, to produce stabilized versions of the glu 3 ,5 basic FGF and eliminate disulfide scrambled forms, are also described.

Inventors

  • 👤 Andrew P. Seddon
  • 👤 Peter Bohlen
  • 👤 Yakov Gluzman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 06:08
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/50; C07K14/503; A; A61; A61P; A61P17/00; A61K; A61K38/00

Claims Analysis

Total Claims: 4
Claim 1
Independent Claim 312 words
A recombinant chimeric basic fibroblast growth factor selected from the group consisting of: (a) a chimeric basic fibroblast growth factor having about 155 amino acids wherein the alanine at position 3 and the serine at position 5 are replaced with glutamic acid; (b) a chimeric basic fibroblast growth factor having about 155 amino acids wherein the alanine at position 3 and the serine at position 5 are replaced with glutamic acid, and the cysteines at positions 78 and 96 are replaced with an amino acid selected from the group consisting of serine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, isoleucine, leucine, valine, phenylalanine, tyrosine, methionine, threonine, proline, alanine, glycine, arginine and tryptophan; and (c) the chimeric basic fibroblast growth factor of (a) or (b) having no N-terminal methionine; wherein the amino acid at positions 78 and 96 are derivatized with a substituent selected from the group consisting of: CH 2 COOH, CH(CO 2 H) (CH 2 ) x (CO 2 H), CH 2 CONR 3 R 4 , R 5 , (CH 2 ) n SO 3 , CHCH 2 CONR 3 CO(CH 2 ) m NR 3 R 4 , CH 2 OCOCH 2 R 5 and SR 6 ; wherein R 3 and R 4 are each H, (CH 2 ) x CO 2 H, CHCO 2 H(CH 2 ) x CO 2 H or C 1 -C 6 alkyl optionally substituted with from 0 to 2 hydroxyl groups or polyethylene glycol; R 5 is C 1 -C 6 alkyl or C 1 -C 4 alkoxymethyl and R 6 is C 1 -C 6 alkyl, polyethylene glycol or phenyl optionally substituted with one or two carboxylic acid or sulfuric acid groups; n is an integer of from 0 to 4; m is an integer of from 2 to 4; and x is an integer of from 1 to 3.
Claim 2
Dependent Claim 312 words
A recombinant chimeric basic fibroblast growth factor selected from the group consisting of: (a) a chimeric basic fibroblast growth factor having about 155 amino acids wherein the alanine at position 3 and the serine at position 5 are replaced with glutamic acid; (b) a chimeric basic fibroblast growth factor having about 155 amino acids wherein the alanine at position 3 and the serine at position 5 are replaced with glutamic acid, and the cysteines at positions 78 and 96 are replaced with an amino acid selected from the group consisting of serine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, isoleucine, leucine, valine, phenylalanine, tyrosine, methionine, threonine, proline, alanine, glycine, arginine and tryptophan; and (c) the chimeric basic fibroblast growth factor of (a) or (b) having no N-terminal methionine; wherein the amino acid at positions 78 and 96 are derivatized with a substituent selected from the group consisting of: CH 2 COOH, CH(CO 2 H) (CH 2 ) x (CO 2 H), CH 2 CONR 3 R 4 , R 5 , (CH 2 ) n SO 3 , CHCH 2 CONR 3 CO(CH 2 ) m NR 3 R 4 , CH 2 OCOCH 2 R 5 and SR 6 ; wherein R 3 and R 4 are each H, (CH 2 ) x CO 2 H, CHCO 2 H(CH 2 ) x CO 2 H or C 1 -C 6 alkyl optionally substituted with from 0 to 2 hydroxyl groups or polyethylene glycol; R 5 is C 1 -C 6 alkyl or C 1 -C 4 alkoxymethyl and R 6 is C 1 -C 6 alkyl, polyethylene glycol or phenyl optionally substituted with one or two carboxylic acid or sulfuric acid groups; n is an integer of from 0 to 4; m is an integer of from 2 to 4; and x is an integer of from 1 to 3.
Claim 3
Dependent Claim 22 words
The recombinant chimeric basic fibroblast growth factor according to claim 1, wherein said chimeric basic fibroblast growth factor is derivatized with carboxymethyl.
Claim 4
Dependent Claim 21 words
The recombinant chimeric basic fibroblast growth factor according to claim 2, wherein said fibroblast growth factor is glu 3 ,5 hbFGF.

References Cited (Backward Citations)

US4296100A Cited
US4378347A Cited
US4588585A Cited
US4785079A Cited
US4902782A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-05-09 1997-11-08 1998-05-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-05-09 2001-11-08 2002-05-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-05-09 2005-11-08 2006-05-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag